What sector does Emcure Pharmaceuticals L belong to?

Emcure Pharmaceuticals L operates in the Healthcare sector, specifically the Pharmaceuticals industry, and is listed on the NSE.

What is the current share price of EMCURE?

As of the latest available quote, EMCURE traded at ₹1,978.90. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of EMCURE?

Emcure Pharmaceuticals L has a price-to-earnings (P/E) ratio of about 37.04. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of EMCURE?

The market capitalisation of Emcure Pharmaceuticals L is approximately ₹37,540 Cr.

Is Emcure Pharmaceuticals L profitable?

For its latest reported financial year, Emcure Pharmaceuticals L recorded a net profit margin of about 10.22%.

Does EMCURE pay a dividend?

Emcure Pharmaceuticals L does not currently show a dividend yield in our data.

What is the return on equity (ROE) of EMCURE?

Emcure Pharmaceuticals L has a return on equity (ROE) of about 20.10%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of EMCURE?

Over the past 52 weeks, EMCURE has traded between a low of ₹1,260.00 and a high of ₹2,048.00.

Emcure Pharmaceuticals L

EMCURE NSE Healthcare Pharmaceuticals

Nifty 500 Smallcap 250

₹1,978.90

+0.82%

Delayed · cached 15 min

Fair value analysis

EMCURE

Emcure Pharmaceuticals L

₹1,962.80

Close used for this calculation

₹1,210.77Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

56/100

Profitability19/25

Returns12/25

Balance Sheet17/25

Efficiency8/25

Growth9/25

Good

Quality radar

Consensus fair value

₹1,210.77

Above FV

▼ -38.3% against the close used

Model range ₹415.13 – ₹1,954.28

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹415.13Fair value₹1,210.77Bull₹1,954.28

FairClose

52-week traded range

52W low ₹1,271.8052W high ₹2,009.60

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Emcure Pharmaceuticals L closed at ₹1,962.80, 62.1% above the consensus fair value of ₹1,210.77 drawn from 8 valuation models.

Financial DNA score 56/100 — Good. P/E of 36.4x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹415.13

-78.9%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

₹562.74

-71.3%

√(22.5 × EPS × BVPS)

EPS=48.76, BVPS=288.65 · outside Graham range (P/E 36.4, P/B 6.8) — asset-light, treat as a rough floor

P/E Fair Value

₹1,740.73

-11.3%

EPS × 35.7x (sector P/E)

EPS=48.76, Sector P/E=35.7x

Peter Lynch (PEG)

₹892.31

-54.5%

EPS × Growth% (PEG = 1 is fair)

EPS=48.76, g=18.3%

EV/EBITDA

₹1,954.28

-0.4%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=21.61B

Book Value (P/B)

₹1,017.48

-48.2%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=288.65, ROE=20.1%, g=6%, r=10%

Reverse DCF

₹1,962.80

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 16.6% | Historical: 18.3%

Margin of Safety

₹679.65

-65.4%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=906.2, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer